Skip to main
PSTV

PSTV Stock Forecast & Price Target

PSTV Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Plus Therapeutics Inc. is advancing its key treatment candidate, rhenium (186Re) obisbemeda, aimed at addressing significant unmet needs in central nervous system cancers, particularly recurrent glioblastoma and leptomeningeal metastases. The favorable reception from the FDA regarding an accelerated approval pathway for Reyobiq, along with the completion of a productive Type B meeting to define pivotal trial strategies, underscores the therapy's potential efficacy and market relevance. Additionally, the recent successful public offering generating approximately $15 million enhances the company's financial position, supporting operational flexibility and manufacturing scalability as it prepares for future clinical trials.

Bears say

The financial outlook for Plus Therapeutics, Inc. appears muted, primarily due to a significant reduction in the 12-month price target from $2.00 to $1.00 per diluted share, following a recent equity offering and potential future dilution from warrant exercises. Additionally, the company's clinical programs targeting recurrent glioblastoma and leptomeningeal metastases face considerable uncertainty, as previous studies have reported median overall survival (OS) rates that vary widely, which may hinder investor confidence. This variability in clinical outcomes, combined with financial dilution concerns, contributes to a negative outlook on the stock.

PSTV has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Plus Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Plus Therapeutics Inc (PSTV) Forecast

Analysts have given PSTV a Strong Buy based on their latest research and market trends.

According to 4 analysts, PSTV has a Strong Buy consensus rating as of Mar 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Plus Therapeutics Inc (PSTV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.